PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsAnti-neutrophil cytoplasmic antibody-associated vasculitis
MeSH D056648 - anti-neutrophil cytoplasmic antibody-associated vasculitis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D056647:Systemic vasculitis
0 Companies
0 Drugs
Success rate
D001327:Autoimmune diseases
1 Company
1 Drug
$
Success rate
D017445:Vascular skin diseases
0 Companies
0 Drugs
Success rate
D056648: 
Anti-neutrophil cytoplasmic antibody-associated vasculitis
2 Companies
1 Drug
$
Success rate
D014890:Granulomatosis with polyangiitis
23 Companies
3 Drugs
$
Success rate
D015267:Churg-strauss syndrome
0 Companies
0 Drugs
Success rate
D055953:Microscopic polyangiitis
8 Companies
3 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
ChemocentryxAvacopan Tavneos 2029-12-21 2021-10-07   
ViforAvacopan Tavneos  2022-01-11   
Clinical Trials
Historical Success Rate
Phase 1
100%
1/1
Phase 2
69%
9/13
Phase 3
21%
3/14
Approved: 1Overall Success rate: 15%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Chemocentryx
Avacopan,
Aspartame
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use